A 57-year-old man presented with blurred vision in his right eye for 2 weeks. Examination (Figure, A) revealed a quiet eye with a well-defined whitish anterior chamber mass, with photographic documentation of serial growth compared with an examination 2 weeks previously. Despite the patient having received oral crizotinib for non–small cell lung cancer, there were new brain metastases. Excisional biopsy and chemotherapy were discussed. The use of 1.25 mg of intracameral bevacizumab led to mass shrinkage before ceritinib was administered for the new brain metastases. The lesion disappeared after 6 weeks, leaving footprints of corneal edema, and thus a biopsy was not performed (Figure, B). There was no recurrence after 4 years and no neovascular glaucoma.
Lam SC, Chong KK, Tham CC. Rapid Growth of Anterior Chamber Metastasis From Presumed Non–Small Cell Lung Cancer During Targeted Therapy, Responding to a Single Intracameral Injection of Anti–Vascular Endothelial-Derived Growth Factor. JAMA Ophthalmol. 2021;139(2):e204096. doi:10.1001/jamaophthalmol.2020.4096
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.